About 100XBIO

100XBIO was founded in 2023 based on 30 expert interviews, proof of concept data and a provisional patent based on 2 successful in vitro experiments. Its origination was funded by the investments of over 10 Facebook medical and biotechnology enthusiasts, "friends and network".

The original name 100X Bioassay was changed to 100XBIO to project bolder vision and wider scope. However, the main innovation stays the new method of research that is based and focused on easily automatable and gentle cell handling.

Our presence in Greater Boston allows us to be close to the heartbeat of the biotech community, stellar academic teams and research sites of pharma companies. If you're around — we can visit your lab or invite you for coffee. Our new lab location will be announced soon!

Our Team

Sergei Pustylnikov

Co-founder, CEO & Inventor

Sergei has spent nearly two decades working across a range of research environments. His work has focused on chronic inflammation, infectious diseases, and cancer immunology — with particular interest in vaccines R&D.

His current interests include adoptive cell therapies and in vivo T cell engineering, gene therapies, and therapeutic antibodies — especially bispecific and multispecific formats that promise precise immune modulation.

Timofei Bondarev

Co-founder, CTO

Timofei spent over a decade in software engineering and process automation, with a series of projects on hardware automation and 3D prototyping. He has experience of managing teams of up to 20 people, angel investing, and founding companies.

We are confident in understanding the problems and needs of research teams, technology feasibility, our skills in designing the methods, building the hardware and software, managing partnerships and engaging communities.

Can we change the world? The short answer is yes.